Annual report pursuant to Section 13 and 15(d)

Term Debt (Details Narrative)

Term Debt (Details Narrative) - USD ($)
$ in Thousands
12 Months Ended
Jan. 01, 2020
Dec. 13, 2019
Dec. 31, 2019
Term debt   $ 8,000  
Matures date   Dec. 31, 2023  
Debt issuance costs   $ 250  
Amortized to interest expense     $ 4
Term debt, description   (i) one-half of one percent (0.50%) above the Prime Rate and (ii) five and one-half percent (5.50%). At December 31, 2019, the interest rate was 5.50%. The Term Debt is collateralized by substantially all assets of the Company. Additionally, the Company has pledged 65% of the outstanding capital stock in the Company's foreign subsidiary, Motus GI Medical Technologies, Ltd., to collateralize the Term Debt.  
Interest rate     6.73%
Cash   $ 3,000  
Bank Least   $ 10,000  
Subsequent Event [Member]      
Term debt, description Interest payments will commence January 1, 2020, following each month until the maturity date. Principal payments will commence January 1, 2022, and continuing for 24 consecutive months thereafter. The Company may prepay all, but not less than all, of the outstanding principal balance of the Term Debt subject to prepayment premium of $240, plus all other sums, if any, that shall have become due and payable.    
SVB [Member]      
Bank Least     $ 10,000